18 May 2018 - - France- and US-based biopharmaceutical company Lysogene (Paris: LYS) has nominated Dr Ralph Laufer as chief scientific officer and member of the executive team, the company said.
Laufer has over 25 years of industry experience in drug discovery, translational research, and drug development at large pharmaceutical and biotechnology companies.
Before joining Lysogene, he was senior vice president at Teva Pharmaceutical Industries in Israel.
Prior to Teva, he was the scientific director of IRBM Science Park, a drug discovery CRO and biotech company in Rome, Italy, as well as head of pharmacology at IRBM-Merck Research Laboratories Rome.
Laufer obtained his PhD in Biochemistry and M.Sc. in Chemistry from the Hebrew University of Jerusalem. He conducted postdoctoral training at the Institut Pasteur in Paris.
Lysogene, a gene therapy company focused on the treatment of orphan diseases of the CNS, has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS.